<DOC>
	<DOCNO>NCT02454270</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , dose-limiting toxicity ( harmful effect drug ) ( DLT ) , maximum tolerate dose ( MTD ) , recommend Phase 2 dose ( RP2D ) preliminary clinical activity duvortuxizumab administer intravenously participant relapse refractory B-cell malignancy [ diffuse-large B cell lymphoma ( DLBCL ) , follicular lymphoma ( FL ) , mantle-cell lymphoma ( MCL ) , chronic lymphocytic leukemia ( CLL ) , acute lymphoblastic leukemia ( ALL ) ] .</brief_summary>
	<brief_title>A Dose Escalation Study Duvortuxizumab Participants With Relapsed Refractory B-cell Malignancies</brief_title>
	<detailed_description>This first human study consist 2 part : ) The dose escalation part b ) The dose expansion part . This openlabel ( participant know identity intervention ) , multicenter ( one study site ) study evaluate safety , establish recommend Phase 2 dose ( RP2D ) , determine preliminary efficacy duvortuxizumab participant relapse refractory B cell malignancy . The dose escalation part trial ( Part 1 ) comprise 3 different patient group base disease indication : Group 1 ( DLBCL , FL , MCL ) ; Group 2 ( CLL ) ; Group 3 ( ALL ) . Dose escalation begin Group 1 initially follow accelerate dose titration design , follow traditional 3+3 design . At dose escalation level treatment second participant initiate least 72 hour observation start first duvortuxizumab dose first participant . Dose escalation Groups 2 3 follow 3+3 design begin initial dose level Group 1 deem safe . Participants [ Group 1 ( DLBCL , FL , MCL ) , Group 2 ( CLL ) Group 3 ( ALL ) ] enrol cohort increase dose level duvortuxizumab administer 28 day treatment cycle . Up 3 RP2Ds may determine Part 1 ( one RP2D Group 1 , one RP2D Group 2 , one RP2D Group 3 ) . In cohort expansion part trial ( Part 2 ) , participant relapse refractory B cell malignancy ( DLBCL , FL , MCL , CLL ALL ) enrol accord tumor type 5 cohort receive duvortuxizumab RP2D determine Part 1 disease type . The study consist 3 period : Screening period ( 28 day prior first dose study drug ) ; Treatment period [ first dose study drug End Treatment Visit ( within 30 day last dose ) ] ; follow period [ End Treatment Visit continue death , lose follow , consent withdrawal , study end ( determine sponsor ) , whichever occur first ] . Number participant achieve overall response Dose Expansion cohort evaluate primarily . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Participants must meet protocol specify hematology chemistry lab parameter criteria Histological confirmation disease document disease relapse last therapy require treatment per treat physician . Participants lymphoma must least 1 measurable site disease ( Part 2 ) . In addition , Bcell malignancy diseasespecific criterion specify protocol must also meet A woman childbearing potential must negative highly sensitive serum [ betahuman chorionic gonadotropin ( βhCG ) ] urine pregnancy test ( minimum sensitivity 25 International unit ( IU ) / liter ( L ) equivalent unit HCG ) within 7 day prior first dose study drug A woman must agree use effective method birth control agree donate egg ( ovum , oocytes ) purpose assist reproduction study 3 month receive last dose study drug A man sexually active woman childbearing potential must agree use barrier method contraception ( eg , condom spermicidal foam/gel/film/cream/suppository ) , man sexually active woman pregnant must use condom men must agree donate sperm 90 day last dose study drug Each participant ( legally acceptable representative ) must sign informed consent form ( ICF ) indicate understands purpose procedure require study willing participate study . Consent obtain prior initiation study related test procedure part standard care participant 's disease History , know central nervous system ( CNS ) involvement cause underlying Bcell malignancy prior history National Cancer Institute common terminology criterion adverse event ( NCI CTCAE ) Grade great equal &gt; = 3 drugrelated CNS toxicity . Participants sign symptom CNS involvement compute tomography ( CT ) magnetic resonance imaging ( MRI ) History know suspect autoimmune disease ( exception : vitiligo , resolve childhood atopic dermatitis , history Grave 's disease euthyroid clinically laboratory test Screening ) Prior allogeneic hematopoietic stemcell transplant subject DLBCL , FL , MCL , CLL . Prior allogenic hematopoietic stemcell transplant permit subject ALL Prior solid organ transplantation Prior treatment therapeutic agent target CD19 and/or CD3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>First-in-Human</keyword>
	<keyword>B-Cell Chronic Lymphocytic Leukemia</keyword>
	<keyword>Diffuse Large-Cell Lymphoma</keyword>
	<keyword>Follicular Lymphoma</keyword>
	<keyword>Mantle-Cell Lymphoma</keyword>
	<keyword>Acute Lymphoid Leukemia</keyword>
	<keyword>Dose Escalation Study</keyword>
	<keyword>Duvortuxizumab</keyword>
</DOC>